Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an...
Read more• 11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro...
Read moreYour Time campaign calls for earlier action in COPDWHO expects COPD to be the third leading cause of death worldwide...
Read moreCollaborations aim to speed research and development approaches in Crohn’s disease and ulcerative colitisIcahn School of Medicine, Massachusetts General Hospital,...
Read morePhase III clinical trial for BI695501, a biosimilar candidate for AbbVie’s Humira®, fully enrolledRecently announced Phase I trial results show...
Read moreStudies show significant improvement with Spiolto® Respimat® in lung function across a range of age groups of patients* with COPD...
Read moreLate breaking data presented at European Lung Cancer Congress 2015 shows delay in disease progression of over a year AstraZeneca...
Read moreAstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive...
Read moreOver 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of...
Read moreAstraZeneca today announced positive topline results from RECAPTURE 1 and RECAPTURE 2, the pivotal Phase III studies evaluating the antibiotic,...
Read more
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
